Incyte Corporation or Grifols, S.A.: Who Manages SG&A Costs Better?

Managing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Grifols, S.A. and Incyte Corporation have demonstrated contrasting approaches to SG&A cost management.

From 2014 to 2023, Grifols, S.A. consistently reported higher SG&A expenses, peaking at approximately 1.25 billion in 2023. This represents a 90% increase from their 2014 figures. In contrast, Incyte Corporation's SG&A expenses grew more modestly, from around 166 million in 2014 to 1.16 billion in 2023, marking a significant 600% increase.

While Grifols, S.A. maintains a steady growth in expenses, Incyte's rapid increase suggests aggressive expansion strategies. Investors and analysts should consider these trends when evaluating the companies' operational efficiencies and long-term strategies.